Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European shares suffer as trade jitters, weak data weigh

Thu, 22nd Mar 2018 17:40

* STOXX 600 down 1.6 pct to 2-week low

* Banks, miners, tech lead sectoral fallers

* Reckitt gains after pulling out of Pfizer race(Adds details, closing prices)

By Helen Reid and Danilo Masoni

LONDON, March 22 (Reuters) - Concerns about trade sentEuropean shares tumbling on Thursday as the United Statesprepared to announce hefty tariffs on Chinese imports, withbanks, basic resources stocks and tech the worst-performing.

U.S. President Donald Trump signed a presidential memorandumthat could impose tariffs on up to $60 billion in Chineseimports.

Separately, the European Union secured an exemption fromU.S. tariffs on steel and aluminium imports set to come intoforce on Friday.

The pan-European STOXX 600 index fell 1.6 percentto its lowest level in more than two weeks, while Germany'sexporter- and industrials-heavy DAX fell 1.7 percent.

The mood was also dampened by a weaker than forecastbusiness activity survey. Euro zone businesses rounded off thefirst quarter of 2018 with their slowest growth in over a year,much weaker than expected, as new business took another hit froma stubbornly strong euro.

"Business sentiment has to be monitored carefully in thecoming months, especially if trade tensions intensify, becauseany further significant deterioration in confidence indicatorsmight signal that the balance of risks starts shifting to thedownside," said UniCredit head of macro research Marco Valli.

Banks, which have been penalized recently weaker thanexpected macro economic data in Europe, were among the leadinglosers on Thursday. Their sectoral index fell 2.5percent to an 11-month low. The sector also suffered after theU.S. Federal Reserve surprised the market with less hawkish rateguidance.

Deutsche Bank declined 2.9 percent, still weakafter sharp losses in the previous session when the bank'sfinance chief said a strong euro and higher funding costs wouldhave a 450 million euro impact on revenues.

Commerzbank tumbled 6.2 percent after a downgradefrom Kepler Cheuvreux.

Basic resources stocks led sectoral losers, down 2.9percent after copper reversed earlier gains to fall tothree-month lows as escalating concern about U.S. plans to levyduties on Chinese imports.

Tech stocks < .SX8P> 2.1 as tariffs on China were expectedto target the high-tech sector.

Chipmakers ams, STMicro, and Infineon, which have led the recent tech stock rally and arefirmly embedded in international supply chains, all fell. .

Deal developments and earnings continued to drive Europeanstock moves.

Reckitt Benckiser shares shone, jumping 4.8 percentafter the British consumer products firm pulled out of thebidding for Pfizer's consumer health unit.

The move reflected relief in the market that Reckitt wouldavoid over-levering or issuing shares for the acquisition.

GlaxoSmithKline, now seen as having a better chanceof buying the Pfizer business, declined 1.7 percent.

Disappointing 2017 results sent United Internetshares down 9.5 percent. Subsidiary Drillisch fell 5.7percent.

Also in tech, Ingenico suffered a 3.4 percent lossafter Kepler Cheuvreux downgraded it, saying full-year guidancenow looked "challenging".

Tech and engineering consultancy Altran fell 3.3percent after launching a share capital increase of 750 millioneuros.

The world’s no.2 cement maker Heidelberg Cementfell 2.3 percent after it announced a dividend slightly short ofanalysts’ average expectations.

Bayer fell 1.4 percent after Australian and EUregulators approved the firm's takeover of Monsanto. "Halfwaythere," wrote UBS analysts, adding all eyes were now on the U.S.Department of Justice, yet to approve the deal.

Overall, with results season drawing to a close, analystswere becoming more negative on the earnings outlook for Europeanstocks.

(Reporting by Helen Reid and Danilo Masoni, Editing by RichardBalmforth and Hugh Lawson)

More News
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more
9 Oct 2023 08:16

TOP NEWS: GSK inks agreement with Zhifei to promote shingles vaccine

(Alliance News) - GSK PLC on Monday said it has reached an exclusive agreement with Chongqing Zhifei Biological Products Ltd to co-promote its shingles vaccine, Shingrix, in China.

Read more
9 Oct 2023 07:42

LONDON BRIEFING: Metro Bank secures deal to shore up finances

(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.

Read more
9 Oct 2023 07:20

GSK inks deal to promote shingles vaccine in China

(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.